225 related articles for article (PubMed ID: 34610109)
1. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P; Veilleux O; Tian L; Sun R; Previtera M; Curran E; Muffly L
Blood Adv; 2022 Mar; 6(5):1608-1618. PubMed ID: 34610109
[TBL] [Abstract][Full Text] [Related]
2. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
[No Abstract] [Full Text] [Related]
3. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
[TBL] [Abstract][Full Text] [Related]
5. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].
Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132
[No Abstract] [Full Text] [Related]
6. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
Li N; Li H
J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
[TBL] [Abstract][Full Text] [Related]
7. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
10. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
12. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
13. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].
Zuo YX; Jia YP; Wu J; Wang JB; Lu AD; Dong LJ; Chang LJ; Zhang LP
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):270-275. PubMed ID: 31104436
[No Abstract] [Full Text] [Related]
14. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
[TBL] [Abstract][Full Text] [Related]
15. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
[TBL] [Abstract][Full Text] [Related]
16. Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
Agrawal V; Murphy L; Pourhassan H; Pullarkat V; Aldoss I
Eur J Haematol; 2024 Feb; 112(2):236-247. PubMed ID: 37772976
[TBL] [Abstract][Full Text] [Related]
17. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
19. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
20. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
